Cycloastragenol (TA-65): What the Evidence Actually Says About the Telomere-Lengthening Compound
Cycloastragenol (TA-65): What the Evidence Actually Says About the Telomere-Lengthening Compound
Few supplements carry a bolder promise than cycloastragenol: a plant compound sold as a "telomerase activator" that claims to lengthen the protective caps on your chromosomes and turn back cellular aging. The story traces to telomere researchers like Calvin Harley and Maria Blasco, and to a 2016 human trial led by Laura Salvador that made headlines for showing telomeres actually got longer. A decade and a 2025 meta-analysis later, we finally have enough human data to separate the real effect from the marketing.
Evidence Tier: 🥈 Silver — Multiple human randomized controlled trials and a meta-analysis, but functional benefit remains unproven and industry funding inflates results.
⚖️ At a Glance: Pros & Cons
⚠️ We are researchers, not doctors. Nothing on this page is medical advice. Cycloastragenol/TA-65 is an unregulated dietary supplement, not an FDA-approved drug. Consult a qualified clinician before taking it — especially if you take prescription medications or have any history of cancer.
✅ Pros
- Real, replicated telomere lengthening: A 2025 meta-analysis of 8 randomized trials (750 people) found TA-65 modestly lengthened telomeres, with a stronger effect in adults over 60.
- Human immune and anti-inflammatory benefits: In elderly heart-attack survivors, TA-65 increased immune cells and lowered the inflammatory marker CRP by 62%.
- Good 12-month safety record: Only mild stomach upset in ~12% of users; no severe adverse events or cancer signals over a year.
- Multiple anti-aging mechanisms: Beyond telomerase, it switches on antioxidant defenses (Nrf2) and cellular cleanup (autophagy), and protects mitochondria.
❌ Cons
- No proven functional benefit: Longer telomeres did not translate into better strength, walking speed, or frailty scores — the "telomere-function disconnect."
- Industry funding inflates results: Company-funded trials reported ~60% larger effects than independent trials.
- Real drug-interaction risk: It inhibits CYP3A4, CYP2E1, and CYP2C19 liver enzymes, which can raise blood levels of statins, blood pressure drugs, and antidepressants.
- Expensive and unproven long-term: Roughly $50–100/month, with no safety or efficacy data beyond 12 months and an unresolved theoretical cancer risk.
📋 Simple Summary
Cycloastragenol (sold as TA-65) is a compound from the Astragalus plant that activates telomerase — an enzyme that rebuilds the protective caps (telomeres) at the ends of your chromosomes. As we age, telomeres get shorter and cells stop dividing, contributing to aging. A 2025 meta-analysis of 8 clinical trials with 750 people found that TA-65 does lengthen telomeres, especially in people over 60. However, longer telomeres did not translate into better physical function or lower inflammation in most studies. A separate trial in heart attack survivors did show increased immune cells and 62% lower inflammation. The compound appears safe over 12 months, with only mild stomach upset in about 12% of users. The big question remains: does making telomeres longer actually make you healthier or live longer? The evidence isn't there yet.
The detailed breakdown continues below for those who want the full science.
What Is Cycloastragenol?
Cycloastragenol (CAG) is a triterpenoid compound derived from Astragalus membranaceus, a plant used in traditional Chinese medicine for centuries. It is the active sapogenin (the non-sugar part) of astragaloside IV — the most abundant saponin in Astragalus root.
TA-65 is the branded, purified form of cycloastragenol, developed and sold by T.A. Sciences (now part of Telomerase Activation Sciences). It was discovered through systematic screening of natural products for telomerase-activating properties and has been sold as a dietary supplement since the mid-2000s.
Cycloastragenol gained fame as one of the first commercially available "telomerase activators" — compounds claimed to slow cellular aging by lengthening telomeres. It remains one of the few such compounds with published human clinical trial data.
How It Works
Cycloastragenol works through multiple mechanisms, only some of which involve telomeres:
- Telomerase activation: CAG binds to telomerase reverse transcriptase (TERT), the catalytic subunit of the telomerase enzyme. This increases the enzyme's ability to add DNA repeats to chromosome ends, lengthening telomeres. Molecular docking studies confirm CAG binds directly to hTERT.
- Mitochondrial protection: TERT exists in two places — the nucleus and mitochondria. Mitochondrial TERT improves the function of Complex I (the first step in cellular energy production) and reduces oxidative stress. TA-65 has been shown to mimic these mitochondrial TERT benefits, protecting heart cells and improving energy metabolism.
- Anti-inflammatory effects: CAG suppresses NF-κB (a master inflammatory switch), activates Nrf2 (the cell's antioxidant defense system), and inhibits the NLRP3 inflammasome — a key driver of age-related inflammation.
- Autophagy enhancement: Through the ERK/TFEB pathway, CAG promotes autophagy — the cellular "housekeeping" process that clears damaged proteins and mitochondria.
- Immune modulation: In the heart attack trial, TA-65 increased all major lymphocyte subsets — CD3+, CD4+, CD8+ T-cells, B-cells, and natural killer cells — suggesting it may partially reverse age-related immune decline (immunosenescence).
The Longevity Connection
Where the evidence actually lands, by outcome:
- Immune aging — 🥈 promising: The strongest human signal. TA-65 raised immune cell counts and cut CRP by 62% in elderly heart-attack survivors (PMID 37086366).
- Telomere length — 🥈 real but downstream: Telomeres do get longer (SMD 0.47 in the meta-analysis), but this is a biomarker, not a health outcome by itself.
- Physical function — ⚠️ unproven: No significant effect on strength, walking speed, or frailty (PMID 41286474).
- Brain, skin, ovaries, joints — 🔭 preclinical only: Animal and cell studies show promise (Alzheimer's, skin aging, ovarian aging, osteoarthritis), but none of this is confirmed in humans yet.
Key Studies
| Study | Design | Key Finding |
|---|---|---|
| 2025 meta-analysis (PMID 41286474) | 8 RCTs, n=750, mean age 63 | Telomeres lengthened (SMD 0.47), but no functional or inflammatory benefit; industry trials inflated effects |
| Heart-attack trial (PMID 37086366) | Double-blind RCT, n=90, age 65+ | 12 months of TA-65 raised immune cells and lowered CRP by 62% |
| Salvador 2016 (PMID 26950204) | Double-blind RCT, n=117, age 53–87 | Low-dose TA-65 lengthened telomeres ~530 bp; placebo lost ~290 bp (company-funded) |
| Harley 2011 (PMID 20822369) | Observational, first human use | Reduced senescent (exhausted) immune T-cells in early adopters |
The 2025 Meta-Analysis: The Big Picture
The most important paper is a 2025 systematic review and meta-analysis published in Cell Biology and Toxicology (PMID 41286474). It pooled data from 8 randomized controlled trials with 750 participants (average age 63):
- Telomere elongation: TA-65 produced moderate telomere lengthening (standardized mean difference = 0.47, p < 0.00001). The effect was larger in adults over 60 (SMD = 0.63 vs 0.36 in younger adults).
- Functional disconnect: Despite longer telomeres, there was NO significant improvement in frailty measures, walking speed, grip strength, or inflammation (CRP/IL-6). The authors called this a "telomere-function disconnect."
- Industry bias: Industry-funded trials reported significantly larger effects (SMD = 0.63 vs 0.40 in independent trials, p = 0.03).
- Safety: Mild GI side effects in 12.4% of users. No severe adverse events or cancer signals over 12 months.
- No dose response: Doses from 10–50 mg/day showed similar effects.
The Heart Attack Trial: Real Functional Benefits?
A notable exception to the functional disconnect comes from a 2023 double-blind RCT in 90 heart attack survivors over 65 (PMID 37086366, published in GeroScience):
- TA-65 (16 mg/day) for 12 months did NOT reduce the primary endpoint (CD8+ TEMRA, a marker of immune aging).
- However, it significantly increased total lymphocyte count (+285 cells/μL), with increases across CD3+, CD4+, CD8+ T-cells, B-cells, and NK cells.
- hsCRP (a key inflammatory marker) was 62% lower in the TA-65 group (1.1 vs 2.9 mg/L).
- The TA-65 group had significantly fewer adverse events (130 vs 185).
This trial stands out because it showed functional immune and inflammatory benefits — not just longer telomeres on a lab report. The population (elderly post-MI patients) may be one where telomerase activation matters most, since immune aging accelerates after a heart attack.
The Landmark 2016 Trial
The first major RCT was published in Rejuvenation Research (PMID 26950204) with 117 adults aged 53–87. After 12 months:
- Low-dose TA-65 (250 Units) increased telomere length by ~530 base pairs (p = 0.005).
- The placebo group actually lost telomere length (−290 bp, p = 0.01).
- The high-dose group (1,000 Units) showed a positive trend that didn't reach significance.
Important caveat: This study was fully funded by T.A. Sciences, and several authors were company employees. The "Units" dosing terminology (rather than milligrams) makes it hard to compare doses across studies.
Emerging Research: Beyond Telomeres
Recent preclinical work is expanding the picture beyond telomeres:
- Alzheimer's disease: CAG improved cognition and reduced amyloid plaques in a mouse model by targeting PDE4B in microglia (PMID 39970860).
- Ovarian aging: CAG-mediated telomerase activation recovered ovarian follicles and improved β-Klotho (an anti-aging protein) in aged mice (PMID 36462538).
- Skin aging: CAG protected human skin cells from UV damage, increased collagen, and improved skin hydration markers (PMID 37474410).
- Kidney disease: CAG protected kidneys in diabetic mice by improving mitochondrial quality control (PMID 41346005).
- Osteoarthritis: CAG restored aging cartilage cells and dampened the inflammatory SASP by balancing Nrf2 and NF-κB signaling (PMID 41813816).
- Metabolism: In roundworms, CAG improved fatty-acid metabolism through the AMPK pathway — a mechanism linked to lifespan extension in animal models (PMID 41596421).
Dosing and Safety
Typical Dosing
| Form | Typical Dose | Notes |
|---|---|---|
| TA-65 (commercial) | 8–16 mg/day | Dose used in the heart-attack trial; taken with food |
| Meta-analysis range | 10–50 mg/day | No clear dose-response — more is not necessarily better |
| Generic cycloastragenol | 5–25 mg/day | Purity varies widely; third-party testing recommended |
Safety Profile (12-Month Data)
- Mild GI side effects: nausea (7.1%), abdominal discomfort (5.3%) — combined 12.4% incidence.
- No severe adverse events or cancer signals over 12 months in the meta-analysis (n=487 with safety data).
- Long-term safety beyond 12 months is unknown — no trials lasting more than one year.
- Theoretical cancer risk: telomerase activation could theoretically promote cancer growth, but no signal has appeared in clinical data to date.
Drug Interactions (⚠️ Important)
A 2026 study (PMID 42107731) found that cycloastragenol inhibits three key liver detoxification enzymes:
- CYP3A4 (IC50 = 13.4 μM) — metabolizes ~50% of all prescription drugs.
- CYP2E1 (IC50 = 15.0 μM).
- CYP2C19 (IC50 = 18.5 μM).
This means cycloastragenol could increase blood levels of drugs metabolized by these enzymes — including statins, blood pressure medications, antidepressants, and many others. Anyone taking prescription medications should discuss TA-65 with their doctor.
❓ Common Questions About Cycloastragenol (TA-65)
What is cycloastragenol (TA-65) and how does it work?
Cycloastragenol is a plant compound from the Astragalus root, sold in purified form as TA-65. It switches on telomerase, the enzyme that rebuilds the protective caps (telomeres) on your chromosomes so cells can keep dividing. It also activates antioxidant defenses and cellular cleanup systems and protects mitochondria.
What does the evidence actually show?
A 2025 meta-analysis of 8 human trials (750 people) confirmed that TA-65 does lengthen telomeres, especially in people over 60 — so the effect is real. But longer telomeres did not lead to better strength, walking speed, or lower inflammation in most studies. The strongest functional evidence comes from a trial in heart-attack survivors, where it raised immune cells and cut inflammation by 62%.
What's the right dose?
The commercial TA-65 product is typically taken at 8–16 mg per day, and the meta-analysis covered a range of 10–50 mg/day with no clear dose-response — so more is not necessarily better. Always start at the lower end and take it with food.
What are the risks and side effects?
The most common side effects are mild stomach upset, nausea, and abdominal discomfort, affecting about 12% of users. No serious side effects appeared over 12 months of study. The bigger concern is a drug interaction: it can slow the liver enzymes that clear many prescription drugs, and there is an unresolved theoretical cancer risk from telomerase activation.
Who should avoid it?
Anyone taking prescription medications (especially statins, blood pressure drugs, or antidepressants), anyone with a history or higher risk of cancer, and people who are pregnant or breastfeeding should avoid TA-65 unless a doctor says otherwise. Healthy adults looking for a clear longevity benefit should know the functional evidence simply isn't there yet.
The Bottom Line
Cycloastragenol is one of the most studied "longevity supplements" with actual human data — 8 RCTs and a meta-analysis is more than most compounds in this space can claim. The telomere-lengthening effect is real and replicated. But the meta-analysis clearly shows that longer telomeres don't automatically mean better health — at least not over 12 months.
The heart attack trial offers the most compelling human evidence of functional benefit (immune restoration, lower inflammation), suggesting TA-65 may work best in people with accelerated immune aging rather than healthy aging adults.
The CYP450 interaction finding is important and under-discussed — if you take prescription medications, this isn't a casual supplement to try without medical supervision.
At $50–100/month for the commercial product, TA-65 is expensive for a supplement with uncertain functional benefits. It sits in the "promising but not proven" category — worth watching as longer trials emerge, but not a first-line longevity intervention.
Our verdict: 🥈 Silver. The biomarker effect is real, but the health benefit is unproven. Who might consider it: adults over 60 specifically interested in immune aging, who are not taking medications metabolized by CYP3A4/2E1/2C19, and who can afford the cost with clear eyes about the limited functional evidence.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Cycloastragenol/TA-65 is a dietary supplement, not an FDA-approved drug. Always consult your doctor before starting any new supplement, especially if you take prescription medications. Full disclaimer →
Sources
- Su et al. "Effects of TA-65 on telomere length, functional outcomes, and inflammation: a systematic review and meta-analysis." Cell Biology and Toxicology (2025). PMID: 41286474
- Bawamia et al. "TA-65 in elderly survivors of acute myocardial infarction." GeroScience (2023). PMID: 37086366
- Salvador L, Singaravelu G, Harley CB, et al. "A Natural Product Telomerase Activator Lengthens Telomeres in Humans: A Randomized, Double Blind, and Placebo Controlled Study." Rejuvenation Research (2016). PMID: 26950204
- Harley CB, Liu W, Blasco M, et al. "A natural product telomerase activator as part of a health maintenance program." Rejuvenation Research (2011). PMID: 20822369
- Luo & Ding. "Cycloastragenol inhibition of cytochrome P450 enzymes." Archives of Biochemistry and Biophysics (2026). PMID: 42107731
- Abdelrahman et al. "Astragalus membranaceus: anti-aging and anticancer properties." Biomolecules (2026). PMID: 42352330
- Yung LY et al. "Astragaloside IV and cycloastragenol stimulate ERK phosphorylation." Planta Medica (2012). PMID: 22083896
- "Cycloastragenol attenuates osteoarthritis by restoring chondrocyte senescence via the NRF2/NF-κB signaling axis." Scientific Reports (2026). PMID: 41813816
- "Cycloastragenol improves fatty acid metabolism through NHR-49/FAT-7 suppression and AAK-2 activation in C. elegans." International Journal of Molecular Sciences (2026). PMID: 41596421